Evolution of total and integrated hiv-1 dna and change in dna sequences in patients with sustained plasma virus suppression

Virology

Volumn 302, Issue 2, 2002, Pages 393-404

  Izopet, Jacques ^a   Cazabat, Michèle ^a   Pasquier, Christophe ^a   Sandres Sauné, Karine ^a   Bonnet, Eric ^a   Marchou, Bruno ^a   Massip, Patrice ^a   Puel, Jacqueline ^a  

^a CHU PURPAN   (France)

Author keywords

Active antiretroviral therapy; HIV 1 DNA; HIV 1 pol and env sequences; Proviral DNA

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BLOOD SAMPLING; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR EVOLUTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036440563     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1621     Document Type: Article

References (55)

1. Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., and Leibowitch, J. (1997). Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease. Science 277, 112-116.
2. Blaak, H., van't Wout, A. B., Brouwer, M., Hooibrink, B., Hovenkamp, E., and Schuitemaker, H. (2000). In vivo HIV-1 infection of CD45RA+CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc. Natl. Acad. Sci. USA 97, 1269-1274.
3. Briggs, D. R., Tuttle, D. L., Sleasman, J. W., and Goodenow, M. M. (2000). Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). Aids 14, 2937-2939.
4. Burton, D. R., and Montefiori, D. C. (1997). The antibody response in HIV-1 infection. Aids 11(Suppl. A), S87-S98.
5. Butler, S. L., Johnson, E. P., and Bushman, F. D. (2002). Human immunodeficiency virus cDNA metabolism: Notable stability of two- long terminal repeat circles. J. Virol. 76, 3739-3747.
6. Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z. Q., Mills, R., McDade, H., Schuwirth, C. M., Goudsmit, J., Danner, S. A., and Haase, A. T. (1997). Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964.
7. Chesebro, B., Wehrly, K., Nishio, J., and Perryman, S. (1996). Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J. Virol. 70, 9055-9059.
8. Cho, M. W., Lee, M. K., Carney, M. C., Berson, J. F., Doms, R. W., and Martin, M. A. (1998). Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72, 2509-2515.
9. Chun, T. W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., Kuo, Y. H., Brookmeyer, R., Zeiger, M. A., Barditch-Crovo, P., and Siliciano, R. F. (1997a). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188.
10. Chun, T. W., Engel, D., Berrey, M. M., Shea, T., Corey, L., and Fauci, A. S. (1998). Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869-8873.
11. Chun, T. W., Finzi, D., Margolick, J., Chadwick, K., Schwartz, D., and Siliciano, R. F. (1995). In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Med. 1, 1284-1290.
12. Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A., Baseler, M., Lloyd, A. L., Nowak, M. A., and Fauci, A. S. (1997b). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197.
13. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R. (1997). Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621-628.
14. Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J. P., Pialoux, G., Raffi, F., and Brun-Vezinet, F. (2000). Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). J. Am. Med. Assoc. 283, 205-211.
15. Dornadula, G., Zhang, H., VanUitert, B., Stern, J., Livornese, L., Jr., Ingerman, M. J., Witek, J., Kedanis, R. J., Natkin, J., DeSimone, J., and Pomerantz, R. J. (1999). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627-1632.
16. Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
17. Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T. C., Chaisson, R. E., Rosenberg, E., Walker, B., Gange, S., Gallant, J., and Siliciano, R. F. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517.
18. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., and Siliciano, R. F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300.
19. Furtado, M. R., Callaway, D. S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A., Perelson, A. S., and Wolinsky, S. M. (1999). Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622.
20. Grossman, Z., Feinberg, M. B., and Paul, W. E. (1998). Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication. Proc. Natl. Acad. Sci. USA 95, 6314-6319.
21. Grossman, Z., Polis, M., Feinberg, M. B., Grossman, Z., Levi, I., Jankelevich, S., Yarchoan, R., Boon, J., de Wolf, F., Lange, J. M., Goudsmit, J., Dimitrov, D. S., and Paul, W. E. (1999). Ongoing HIV dissemination during HAART. Nature Med. 5, 1099-1104.
22. Gunthard, H. F., Frost, S. D., Leigh-Brown, A. J., Ignacio, C. C., Kee, K., Perelson, A. S., Spina, C. A., Havlir, D. V., Hezareh, M., Looney, D. J., Richman, D. D., and Wong, J. K. (1999). Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73, 9404-9412.
23. Gunthard, H. F., Wong, J. K., Ignacio, C. C., Guatelli, J. C., Riggs, N. L., Havlir, D. V., and Richman, D. D. (1998). Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72, 2422-2428.
24. Hermankova, M., Ray, S. C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquil, R. T., Quinn, T. C., Siliciano, J. D., Siliciano, R. F., and Persaud, D. (2001). HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. J. Am. Med. Assoc. 286, 224-226.
25. Hirsch, M. S., Brun-Vezinet, F., RT, D. A., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., Demeter, L. M., Vella, S., Jacobsen, D. M., and Richman, D. D. (2000). Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J. Am. Med. Assoc. 283, 2417-2426.
26. Hockett, R. D., Kilby, J. M., Derdeyn, C. A., Saag, M. S., Sillers, M., Squires, K., Chiz, S., Nowak, M. A., Shaw, G. M., and Bucy, R. P. (1999). Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J. Exp. Med. 189, 1545-1554.
27. Holtkamp, N., Otteken, A., Findhammer, S., Miller, V., Kurth, R., and Werner, A. (2000). Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy. J. Infect. Dis. 181, 513-521.
28. Hung, C. S., Vander Heyden, N., and Ratner, L. (1999). Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J. Virol. 73, 8216-8226.
29. Izopet, J., Salama, G., Pasquier, C., Sandres, K., Marchou, B., Massip, P., and Puel, J. (1998a). Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 19, 478-483.
30. Izopet, J., Tamalet, C., Pasquier, C., Sandres, K., Marchou, B., Massip, P., and Puel, J. (1998b). Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay. J. Med. Virol. 54, 54-59.
31. Kwok, S., and Higushi, R. (1989). Avoiding false positives with PCR. Nature 339, 237-238.
32. Lafeuillade, A., Chollet, L., Hittinger, G., Profizi, N., Costes, O., and Poggi, C. (1998). Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. J. Infect. Dis. 177, 235-238.
33. Liu, S. L., Rodrigo, A. G., Shankarappa, R., Learn, G. H., Hsu, L., Davidov, O., Zhao, L. P., and Mullins, J. I. (1996). HIV quasispecies and resampling. Science 273, 415-416.
34. Martinez, M. A., Cabana, M., Ibanez, A., Clotet, B., Arno, A., and Ruiz, L. (1999). Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256, 180-187.
35. Myers, L. E., McQuay, L. J., and Hollinger, F. B. (1994). Dilution assay statistics. J. Clin. Microbiol. 32, 732-739.
36. Natarajan, V., Bosche, M., Metcalf, J. A., Ward, D. J., Lane, H. C., and Kovacs, J. A. (1999). HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 353, 119-120.
37. Ostrowski, M. A., Chun, T. W., Justement, S. J., Motola, I., Spinelli, M. A., Adelsberger, J., Ehler, L. A., Mizell, S. B., Hallahan, C. W., and Fauci, A. S. (1999). Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J. Virol. 73, 6430-6435.
38. Pakker, N. G., Notermans, D. W., de Boer, R. J., Roos, M. T., de Wolf, F., Hill, A., Leonard, J. M., Danner, S. A., Miedema, F., and Schellekens, P. T. (1998). Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med. 4, 208-214.
39. Pasquier, C., Cayrou, C., Blancher, A., Tourne-Petheil, C., Berrebi, A., Tricoire, J., Puel, J., and Izopet, J. (1998). Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J. Virol. 72, 8493-8501.
40. Pierson, T., Hoffman, T. L., Blankson, J., Finzi, D., Chadwick, K., Margolick, J. B., Buck, C., Siliciano, J. D., Doms, R. W., and Siliciano, R. F. (2000). Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J. Virol. 74, 7824-7833.
41. Pierson, T. C., Kieffer, T. L., Ruff, C. T., Buck, C., Gange, S. J., and Siliciano, R. F. (2002). Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J. Virol. 76, 4138-4144.
42. Ramratnam, B., Mittler, J. E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C. A., Perelson, A. S., Markowitz, M., and Ho, D. D. (2000). The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Med. 6, 82-85.
43. Saitou, N., and Nei, M. (1987). The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425.
44. Schrager, L. K., and D'Souza, M. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. J. Am. Med. Assoc. 280, 67-71.
45. Shankarappa, R., Margolick, J. B., Gange, S. J., Rodrigo, A. G., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C. R., Learn, G. H., He, X., Huang, X. L., and Mullins, J. I. (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489-10502.
46. Sharkey, M. E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan, J. L., Bucy, R. P., Kostrikis, L. G., Haase, A., Veryard, C., Davaro, R. E., Cheeseman, S. H., Daly, J. S., Bova, C., Ellison, R. T., 3rd, Mady, B., Lai, K. K., Moyle, G., Nelson, M., Gazzard, B., Shaunak, S., and Stevenson, M. (2000). Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nature Med. 6, 76-81.
47. Simmons, G., Wilkinson, D., Reeves, J. D., Dittmar, M. T., Beddows, S., Weber, J., Carnegie, G., Desselberger, U., Gray, P. W., Weiss, R. A., and Clapham, P. R. (1996). Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70, 8355-8360.
48. Taylor, J. R., Jr., Kimbrell, K. C., Scoggins, R., Delaney, M., Wu, L., and Camerini, D. (2001). Expression and function of chemokine receptors on human thymocytes: Implications for infection by human immunodeficiency virus type 1. J. Virol. 75, 8752-8760.
49. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1996). CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680.
50. Trumpfheller, C., Tenner-Racz, K., Racz, P., Fleischer, B., and Frosch, S. (1998). Expression of macrophage inflammatory protein (MIP)-1al-pha, MIP-1beta, and RANTES genes in lymph nodes from HIV+ individuals: Correlation with a Th1-type cytokine response. Clin. Exp. Immunol. 112, 92-99.
51. Van't Wout, A. B., de Jong, M. D., Kootstra, N. A., Veenstra, J., Lange, J. M., Boucher, C. A., and Schuitemaker, H. (1996). Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: A clonal analysis. J. Infect. Dis. 174, 845-849.
52. Wong, J. K., Hezareh, M., Gunthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., and Richman, D. D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295.
53. Xiao, L., Owen, S. M., Goldman, I., Lal, A. A., deJong, J. J., Goudsmit, J., and Lal, R. B. (1998). CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 240, 83-92.
54. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., and Chen, I. S. (1990). HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222.
55. Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., Markowitz, M., and Ho, D. D. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613.